Investment bankers who were advising Shire on its proposed $54 billion merger with AbbVie in 2014, only to see the deal collapse, have not had to wait long for a fresh shot at a bumper payday from the Dublin-based pharmaceuticals giant.

Shire announced on January 11 that it had agreed a $32 billion cash-and-stock tie-up with its US-based peer Baxalta.